General information with sources. Never a substitute for your doctor.
Randomized controlled trial
At 40 weeks, HbA1c fell by 1.69, 1.86 and 1.94 points with retatrutide 4, 9 and 12 mg, compared with 0.81 on placebo; the differences were −0.88 (95% CI, −1.18 to −0.59), −1.04 (95% CI, −1.32 to −0.76) and −1.12 points (95% CI, −1.39 to −0.85).
Bajaj HS et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. The Lancet, 2026. DOI: 10.1016/S0140-6736(26)00967-0
No clinical review. No advertising from drug companies and no affiliate links.How we work
At 40 weeks, HbA1c fell by 1.69, 1.86 and 1.94 points with retatrutide 4, 9 and 12 mg, compared with 0.81 on placebo; the differences were −0.88 (95% CI, −1.18 to −0.59), −1.04 (95% CI, −1.32 to −0.76) and −1.12 points (95% CI, −1.39 to −0.85). Weight changed by −11.5%, −13.9% and −15.3% with the three doses, compared with −2.6% on placebo. The most common adverse effects were digestive, generally mild or moderate and decreasing over time; between 2 and 5% of participants on retatrutide stopped treatment because of adverse effects, compared with none on placebo. There was no severe hypoglycemia.
Funded by Eli Lilly, which is developing retatrutide. It lasted 40 weeks and included only people with short-duration type 2 diabetes who were not taking other diabetes drugs. It was compared with placebo, not with other treatments. Retatrutide is an investigational drug.
In people with short-duration type 2 diabetes who were not taking other diabetes drugs, retatrutide markedly lowered HbA1c and weight over 40 weeks. It is an investigational drug and these data come from a single placebo-controlled trial. They are not a basis for choosing a treatment today.
The original paper and the records consulted for this summary, with the date they were accessed.